** Eli Lilly LLY.N stock climbing 0.1% on Mon after announcing it will ship higher doses of weight-loss drug Zepbound to cash-paying customers starting early Aug
** The modest gain in LLY lagged a ~1% rally in the S&P 500 .SPX, and outperformed a 0.32% dip in the S&P 500 healthcare sector index .SPXHC
** Co to offer 12.5 mg and 15 mg doses on its website for $499/month or less, regardless of insurance status; doctors can prescribe from July 7
** Move aims to counter competition from compounded versions and cheaper copies in the $150 bln obesity drug market
** LLY's stock up about 6% YTD, outperforming S&P 500's ~3% rise
** Stock recently traded at 32x expected earnings, just below its 5-year avg forward PE of 35
** LLY's stock is about 16% below its 52-week intraday high of $972.24 reached on Aug. 27, 2024
(Reporting by Noel Randewich)
((noel.randewich@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。